In July 9th post, I commented on KV's decision to sue FDA over the latter's non-enforcement of compounders competing with KV's Makena. I said it was only a matter of time before KV goes out of business.
KV sink .
We're one step closer now as KV filed for bankruptcy protection today. KV said the FDA's lax enforcement has prevented it from realizing its "full value" for Makena -- i.e. they couldn't charge $1500 per dose for a product that previously cost the patient $10. So now they are left with $728 M in debts and only $237 M in assets.
Posted by Bruce Lehr Aug 6th 2012.